Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line

Frank Martiniuk, Agnes Chen, Vincent Donnabella, Eleni Arvanitopoulos, Alfred E. Slonim, Nina Raben, Paul Plotz, William N. Rom

Research output: Contribution to journalArticle

Abstract

Inherited genetic deficiency of lysosomal acid alpha glucosidase or acid maltase (GAA) results in the autosomal recessive glycogen storage disease type II (GSD II). To investigate whether we could generate a functional recombinant human GAA (rhGAA) for enzyme replacement therapy, we subcloned the cDNAs for human GAA and mouse dihydrofolate reductase (DHFR) into DHFR(neg) Chinese hamster ovary cells and established a stable cotransformant that expressed rhGAA. We cultured the recombinant cells in media with progressively increasing concentrations of methotrexate and found that human GAA enzyme activity increased to over 2,000 IU per gram protein. Importantly, the human GAA enzyme activity correlated to equivalent amounts of human GAA protein by rocketimmunoelectrophoresis. We confirmed that the human GAA enzyme activity corresponded to an amplification in human GAA mRNA by Northern analysis and human GAA cDNA copy number by Southern analysis. Exposing the rhGAA to human GSDII fibroblast cells or patient's lymphocytes or monocytes resulted in uptake of the rhGAA and reversal of the enzymatic defect. Mannose-6-phosphate in the media blocked uptake. GAA -/- mice were treated with the rhGAA at 1 mg/kg, which resulted in heterozygous levels of GAA in tissues, most notably skeletal muscle, heart and diaphragm after two infusions. More importantly, after multiple infusions, hind, and fore-limb muscle weakness was reversed. This rhGAA would be ideal for enzyme replacement therapy in GSD II. (C) 2000 Academic Press.

Original languageEnglish (US)
Pages (from-to)917-923
Number of pages7
JournalBiochemical and Biophysical Research Communications
Volume276
Issue number3
DOIs
StatePublished - Oct 5 2000
Externally publishedYes

Fingerprint

Glycogen Storage Disease Type II
Tetrahydrofolate Dehydrogenase
Enzyme activity
Glycogen
alpha-Glucosidases
Cells
Cell Line
Muscle
Enzymes
Complementary DNA
Lymphocytes
Fibroblasts
Diaphragms
Methotrexate
Amplification
Tissue
Messenger RNA
Defects
Enzyme Replacement Therapy
Acids

Keywords

  • Acid maltase
  • Glycogen storage disease type II
  • Methotrexate
  • Over-expression CHO cell line
  • Pompe's disease
  • Recombinant human acid maltase (rhGAA)

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line. / Martiniuk, Frank; Chen, Agnes; Donnabella, Vincent; Arvanitopoulos, Eleni; Slonim, Alfred E.; Raben, Nina; Plotz, Paul; Rom, William N.

In: Biochemical and Biophysical Research Communications, Vol. 276, No. 3, 05.10.2000, p. 917-923.

Research output: Contribution to journalArticle

Martiniuk, Frank ; Chen, Agnes ; Donnabella, Vincent ; Arvanitopoulos, Eleni ; Slonim, Alfred E. ; Raben, Nina ; Plotz, Paul ; Rom, William N. / Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line. In: Biochemical and Biophysical Research Communications. 2000 ; Vol. 276, No. 3. pp. 917-923.
@article{9fa92a65b7ff456b8b2a05167ffc827c,
title = "Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line",
abstract = "Inherited genetic deficiency of lysosomal acid alpha glucosidase or acid maltase (GAA) results in the autosomal recessive glycogen storage disease type II (GSD II). To investigate whether we could generate a functional recombinant human GAA (rhGAA) for enzyme replacement therapy, we subcloned the cDNAs for human GAA and mouse dihydrofolate reductase (DHFR) into DHFR(neg) Chinese hamster ovary cells and established a stable cotransformant that expressed rhGAA. We cultured the recombinant cells in media with progressively increasing concentrations of methotrexate and found that human GAA enzyme activity increased to over 2,000 IU per gram protein. Importantly, the human GAA enzyme activity correlated to equivalent amounts of human GAA protein by rocketimmunoelectrophoresis. We confirmed that the human GAA enzyme activity corresponded to an amplification in human GAA mRNA by Northern analysis and human GAA cDNA copy number by Southern analysis. Exposing the rhGAA to human GSDII fibroblast cells or patient's lymphocytes or monocytes resulted in uptake of the rhGAA and reversal of the enzymatic defect. Mannose-6-phosphate in the media blocked uptake. GAA -/- mice were treated with the rhGAA at 1 mg/kg, which resulted in heterozygous levels of GAA in tissues, most notably skeletal muscle, heart and diaphragm after two infusions. More importantly, after multiple infusions, hind, and fore-limb muscle weakness was reversed. This rhGAA would be ideal for enzyme replacement therapy in GSD II. (C) 2000 Academic Press.",
keywords = "Acid maltase, Glycogen storage disease type II, Methotrexate, Over-expression CHO cell line, Pompe's disease, Recombinant human acid maltase (rhGAA)",
author = "Frank Martiniuk and Agnes Chen and Vincent Donnabella and Eleni Arvanitopoulos and Slonim, {Alfred E.} and Nina Raben and Paul Plotz and Rom, {William N.}",
year = "2000",
month = "10",
day = "5",
doi = "10.1006/bbrc.2000.3555",
language = "English (US)",
volume = "276",
pages = "917--923",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line

AU - Martiniuk, Frank

AU - Chen, Agnes

AU - Donnabella, Vincent

AU - Arvanitopoulos, Eleni

AU - Slonim, Alfred E.

AU - Raben, Nina

AU - Plotz, Paul

AU - Rom, William N.

PY - 2000/10/5

Y1 - 2000/10/5

N2 - Inherited genetic deficiency of lysosomal acid alpha glucosidase or acid maltase (GAA) results in the autosomal recessive glycogen storage disease type II (GSD II). To investigate whether we could generate a functional recombinant human GAA (rhGAA) for enzyme replacement therapy, we subcloned the cDNAs for human GAA and mouse dihydrofolate reductase (DHFR) into DHFR(neg) Chinese hamster ovary cells and established a stable cotransformant that expressed rhGAA. We cultured the recombinant cells in media with progressively increasing concentrations of methotrexate and found that human GAA enzyme activity increased to over 2,000 IU per gram protein. Importantly, the human GAA enzyme activity correlated to equivalent amounts of human GAA protein by rocketimmunoelectrophoresis. We confirmed that the human GAA enzyme activity corresponded to an amplification in human GAA mRNA by Northern analysis and human GAA cDNA copy number by Southern analysis. Exposing the rhGAA to human GSDII fibroblast cells or patient's lymphocytes or monocytes resulted in uptake of the rhGAA and reversal of the enzymatic defect. Mannose-6-phosphate in the media blocked uptake. GAA -/- mice were treated with the rhGAA at 1 mg/kg, which resulted in heterozygous levels of GAA in tissues, most notably skeletal muscle, heart and diaphragm after two infusions. More importantly, after multiple infusions, hind, and fore-limb muscle weakness was reversed. This rhGAA would be ideal for enzyme replacement therapy in GSD II. (C) 2000 Academic Press.

AB - Inherited genetic deficiency of lysosomal acid alpha glucosidase or acid maltase (GAA) results in the autosomal recessive glycogen storage disease type II (GSD II). To investigate whether we could generate a functional recombinant human GAA (rhGAA) for enzyme replacement therapy, we subcloned the cDNAs for human GAA and mouse dihydrofolate reductase (DHFR) into DHFR(neg) Chinese hamster ovary cells and established a stable cotransformant that expressed rhGAA. We cultured the recombinant cells in media with progressively increasing concentrations of methotrexate and found that human GAA enzyme activity increased to over 2,000 IU per gram protein. Importantly, the human GAA enzyme activity correlated to equivalent amounts of human GAA protein by rocketimmunoelectrophoresis. We confirmed that the human GAA enzyme activity corresponded to an amplification in human GAA mRNA by Northern analysis and human GAA cDNA copy number by Southern analysis. Exposing the rhGAA to human GSDII fibroblast cells or patient's lymphocytes or monocytes resulted in uptake of the rhGAA and reversal of the enzymatic defect. Mannose-6-phosphate in the media blocked uptake. GAA -/- mice were treated with the rhGAA at 1 mg/kg, which resulted in heterozygous levels of GAA in tissues, most notably skeletal muscle, heart and diaphragm after two infusions. More importantly, after multiple infusions, hind, and fore-limb muscle weakness was reversed. This rhGAA would be ideal for enzyme replacement therapy in GSD II. (C) 2000 Academic Press.

KW - Acid maltase

KW - Glycogen storage disease type II

KW - Methotrexate

KW - Over-expression CHO cell line

KW - Pompe's disease

KW - Recombinant human acid maltase (rhGAA)

UR - http://www.scopus.com/inward/record.url?scp=0034609942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034609942&partnerID=8YFLogxK

U2 - 10.1006/bbrc.2000.3555

DO - 10.1006/bbrc.2000.3555

M3 - Article

VL - 276

SP - 917

EP - 923

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -